NCT02674581

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

An Open-label Study to Evaluate the Pharmacokinetics and Safety of BMS-663068 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-Stage Renal Dysfunction

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Oral BMS-663068 (pro-drug)	Oral BMS-663068 (pro-drug), metabolized to active BMS-626529

Timeline

• Start date: 2016-02-26
• Primary completion: 2016-05-24
• Completion: 2016-05-24
• First posted: 2016-02-04
• Last updated: 2018-05-15

Locations

1 site across 1 country: United States